Qty: 100 μg/200 µL Mouse anti-erbB3/HER3

Catalog No. 433160 Mouse anti-erbB3/HER3

FORM This affinity-purified mouse monoclonal antibody is supplied as a 200 µL aliquot at a concentration of 0.5 mg/mL in PBS, pH 7.4, containing 0.1% sodium azide. This antibody is highly purified from mouse ascites by A/G chromatography.

Clone: 126T21 Isotype: IgG1

IMMUNOGEN Recombinant protein derived from the C-terminus of human erbB3/HER3 protein

SPECIFICITY This antibody is specific for human erbB3/HER3 (erythroblastic viral oncogen homology 3, c-erb3) protein (accession # P21860, NP_001973.2). The immunogen is also 99% similar to chimpanzee, 97% similar to rhesus monkey, 94% to horse, 91% to mouse, 90% to dog and rat, 89% to pig and 87% similar to bovine erbB3/HER3 sequence. On Western blots of human HeLa and rat L6 cell lysates, it identifies the target band at ~185 kDa.

REACTIVITY Reactivity has been confirmed with human HeLa and rat L6 cell lysates using Western blotting. Based on amino acid , reactivity with chimpanzee, rhesus monkey, horse, mouse, dog and pig is also expected.

Sample Western Blotting Immunoprecipitation Immunofluorescence Human +++ 0 (no reactivity) ND Rat +++ ND ND Monkey (Rhesus) ND ND ND Pig ND ND ND Bovine ND ND ND Mouse ND ND ND Chimpanzee ND ND ND Horse ND ND ND (Excellent +++, Good ++, Poor +, No reactivity 0, Not applicable N/A, Not determined ND)

USAGE Working concentrations for specific applications should be determined by the investigator. Appropriate concentrations will be affected by several factors, including secondary antibody affinity, antigen concentration, sensitivity of detection method, temperature and length of incubations, etc. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.

Western Blotting: 2 µg/mL Immunofluorescence: ND Immunoprecipitation: No reactivity

(cont’)

www.invitrogen.com Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [email protected] PI 433160 (Rev 09/08) DCC-08-1535 Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use. (433160 cont’d)

STORAGE Store at 2-8°C for up to one month. Store at –20°C for long-term storage. Avoid repeated freezing and thawing.

BACKGROUND ErbB3/Her3 encodes a member of the epidermal (EGFR) family of receptor tyrosine kinases. The membrane spanning protein has a neuregulin binding domain but not an active kinase domain.1 It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. Neuregulin induces ErbB3 downregulation. This is mediated by protein stability cascade involving ubiquitin/deubiquitin pathway members USP8 and Nrdp1.2 Kinase activity of the complex is achieved by Her3 heterodimerization with other EGF receptor family members which do have kinase activity. This leads to the activation of pathways which lead to cell proliferation or differentiation. Downstream Her3 interacts with the PI3K/Akt pathway, but also with GRB, SHC, SRC, ABL, rasGAP, SYK and transcriptional regulator EBP1.1 Amplification of this and/or overexpression of its protein have been reported in numerous , including prostate, bladder, and breast tumors. Alternatively spliced isoform lacks the intermembrane region and is secreted outside the cell. This p45-sErbB3 is secreted by prostate cells and it is able to promote bone formation.3 Additional splice variants have also been reported, but they have not been thoroughly characterized. Small inhibitory RNA (siRNA) to ErbB3 or AKT is showing promise as a therapeutic approach to treatment of lung adenocarcinoma.

REFERENCES 1. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther. 2008 Jul;15(7):413-48. 2. Cao Z, Wu X, Yen L, Sweeney C, Carraway KL 3rd. Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin Nrdp1. Mol Cell Biol. 2007 Mar;27(6):2180-8. 3. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. . 2008 May 19.

RELATED PRODUCTS Product Conjugate Cat. No. Protein A Sepharose 4B 10-1041 rec-Protein G Sepharose 4B 10-1241 ZyMAX™ Goat anti-rabbit IgG Unconjugated 81-6100 ZyMAX™ Goat anti-mouse IgG Unconjugated 81-6500

Secondary antibody conjugates. Goat anti-rabbit IgG Goat anti-mouse IgG Fluorescence Conjugate Ex/Em* (H+L) (H+L) similar to-- Alexa Fluor® 488 A11008 A11001 495/519 FITC Alexa Fluor® 555 A21428 A21422 555/565 Cy3 Alexa Fluor® 594 A11012 A11005 590/617 Texas Red Alexa Fluor® 647 A21244 A21235 650/668 Cy5 HRP 81-6120 81-6520 NA** NA AP 81-6122 81-6522 NA NA Biotin B2770 B2763 NA NA *Excitation/emission (nm); **Not applicable

For additional secondary antibody conjugates, visit www.invitrogen.com/antibodies

For Research Use Only

www.invitrogen.com Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [email protected] PI 433160 (Rev 09/08) DCC-08-1535 Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.